HMG CoA reductase inhibitors (statins) for kidney transplant recipients

Sankar D. Navaneethan, Vlado Perkovic, Sagar U Nigwekar, David W. Johnson, Jonathan C. Craig, Giovanni F.M. Strippoli

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To evaluate the effects of statin therapy on mortality and the risk of subsequent cardiovascular outcomes in kidney transplant recipients

To evaluate the effects of statin therapy on graft function, including the incidence of acute rejection and chronic allograft nephropathy.

To evaluate the effects of statin therapy on the risk of acute transplant rejection.

To evaluate the risk of drug or dosage related adverse events when statin therapy is used in kidney transplant recipients.
Original languageEnglish
Article numberCD005019
JournalCochrane Database of Systematic Reviews
Issue number2
Publication statusPublished - 21 Jan 2009

Keywords

  • kidney transplantation
  • cardiovascular disease
  • Lipoprotein profile

Fingerprint Dive into the research topics of 'HMG CoA reductase inhibitors (statins) for kidney transplant recipients'. Together they form a unique fingerprint.

  • Cite this

    Navaneethan, S. D., Perkovic, V., Nigwekar, S. U., Johnson, D. W., Craig, J. C., & Strippoli, G. F. M. (2009). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, (2), [CD005019].